Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status-Reference-Cited by-同舟云学术

Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status

Published:2014-08 Issue:4 Volume:23 Page:466-472
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Tanioka Maki,Sasaki Masaoki,Shimomura Akihiko,Fujishima Makoto,Doi Mihoko,Matsuura Kazuo,Sakuma Toshiko,Yoshimura Kenichi,Saeki Toshiaki^ORCID,Ohara Masahiro,Tsurutani Junji,Watatani Masahiro,Takano Toshimi^ORCID,Kawabata Hidetaka^ORCID,Mukai Hirofumi,Naito Yoichi,Hirokaga Koichi,Takao Shintaro,Minami Hironobu

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference22 articles.

1. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer;Fisher;J Clin Oncol,1998

2. Preoperative chemotherapy for women with operable breast cancer;Mieog;Cochrane Database Syst Rev,2007

3. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy;Kuerer;J Clin Oncol,1999

4. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes;von Minckwitz;J Clin Oncol,2012

5. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27;Bear;J Clin Oncol,2006

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of oedema and shrinkage patterns for prediction of response to neoadjuvant chemotherapy and survival outcomes in luminal breast cancer;Clinical Radiology;2024-08

2. New insights into breast microcalcification for poor prognosis: NACT cohort and bone metastasis evaluation cohort;Journal of Cancer Research and Clinical Oncology;2023-03-14

3. Pegylated Liposomal Doxorubicin, Docetaxel, and Trastuzumab as Neoadjuvant Treatment for HER2-Positive Breast Cancer Patients: A Phase II and Biomarker Study;Frontiers in Oncology;2022-07-08

4. Pathological complete response as a surrogate to improved survival in human epidermal growth factor receptor-2-positive breast cancer: systematic review and meta-analysis;BJS Open;2022-05-02

5. Clinical and Genetic Predictive Models for the Prediction of Pathological Complete Response to Optimize the Effectiveness for Trastuzumab Based Chemotherapy;Frontiers in Oncology;2021-07-15